**Supplemental Table 1.** Information for the patients who developed irAEs in the COVID-19 positive group.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Age,**  **year** | **Gender** | **Cancer type** | **ICI type** | **Time from last ICI to COVID-19, days** | **Time from COVID-19 to irAE, days** | **History of irAE before COVID-19 infection** | **irAE type** |
| 63 | F | NSCLC | Pembrolizumab | 19 | 35 | No | Colitis |
| 46 | M | NSCLC | Pembrolizumab | -30\* | 117 | No | Nephritis |
| 69 | F | NSCLC | Pembrolizumab | 21 | 224 | No | Pneumonitis |
| 65 | M | NSCLC | Nivolumab | 0 | 256 | No | Adrenal insufficiency |
| 80 | F | SCLC | Durvalumab | 8 | 69 | No | Colitis |
| 61 | F | Renal cell | Pembrolizumab | 17 | 314 | No | Colitis |
| 69 | F | Endometrial | Pembrolizumab | 0 | 132 | Yes\*\* | Colitis |
| 57 | M | Bladder | Pembrolizumab | 0 | 192 | No | Dermatitis/rash |
| 71 | F | Uterine | Pembrolizumab | 0 | 130 | No | Dermatitis/rash |
| 77 | M | Uterine | Pembrolizumab | 0 | 8 | Yes\*\*\* | Hypothyroidism |
| 78 | F | Ovarian | Pembrolizumab | 0 | 34 | No | Ocular toxicity |
| 66 | F | Hepatocellular | Pembrolizumab | 0 | 33 | No | Dermatitis/rash |
| 46 | F | Melanoma | I + N | 28 | 187 | No | Hepatitis |
| 78 | F | Bladder small cell | Atezolizumab | 1 | 72 | No | Hepatitis |

*Abbreviations:* irAE, immune-related adverse events; ICI, immune checkpoint inhibitor; Pt, patient; F, female; M, male; I + N: ipilimumab + nivolumab; COVID-19, coronavirus disease 2019; NSCLS, non-small cell lung cancer; SCLC, small cell lung cancer.

\* First cycle of pembrolizumab was started 30 days after COVID-19 infection.

\*\* Grade 1 dermatitis/rash three month before COVID-19 infection.

\*\*\* Grade 1 dermatitis/rash two month before COVID-19 infection.